Ashfield Capital Partners LLC reduced its position in Amgen, Inc. (NASDAQ:AMGN) by 2.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 61,149 shares of the medical research company’s stock after selling 1,286 shares during the period. Amgen accounts for about 1.5% of Ashfield Capital Partners LLC’s holdings, making the stock its 13th biggest holding. Ashfield Capital Partners LLC’s holdings in Amgen were worth $11,401,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the company. Welch Group LLC purchased a new stake in Amgen during the 2nd quarter valued at approximately $639,000. DekaBank Deutsche Girozentrale raised its stake in Amgen by 2.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock valued at $152,927,000 after acquiring an additional 24,219 shares during the last quarter. Pacer Advisors Inc. raised its stake in Amgen by 10.3% during the 2nd quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock valued at $4,371,000 after acquiring an additional 2,362 shares during the last quarter. Wesbanco Bank Inc. raised its stake in Amgen by 6.5% during the 2nd quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock valued at $18,393,000 after acquiring an additional 6,492 shares during the last quarter. Finally, Coho Partners Ltd. raised its stake in Amgen by 25.8% during the 2nd quarter. Coho Partners Ltd. now owns 1,034,651 shares of the medical research company’s stock valued at $178,198,000 after acquiring an additional 212,213 shares during the last quarter. 78.48% of the stock is owned by institutional investors and hedge funds.
Several analysts have commented on AMGN shares. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective for the company. in a research note on Wednesday, January 3rd. Mizuho reaffirmed a “buy” rating and set a $198.00 price objective (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. BMO Capital Markets reaffirmed a “hold” rating and set a $198.00 price objective on shares of Amgen in a research note on Friday, October 20th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $200.00 price objective on shares of Amgen in a research note on Monday, September 25th. Fifteen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $190.15.
Amgen, Inc. (NASDAQ AMGN) opened at $189.28 on Friday. The stock has a market capitalization of $138,640.00, a P/E ratio of 17.10, a PEG ratio of 2.75 and a beta of 1.36. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the prior year, the business posted $3.02 EPS. research analysts anticipate that Amgen, Inc. will post 12.71 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.79%. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio is 41.55%.
Amgen announced that its board has authorized a share repurchase program on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,575 shares of company stock valued at $1,508,836. Company insiders own 0.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Ashfield Capital Partners LLC Has $11.40 Million Stake in Amgen, Inc. (AMGN)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/20/ashfield-capital-partners-llc-has-11-40-million-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.